|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Argmann C and Auwerx J: Insulin secretion:
SIRT4 gets in on the act. Cell. 126:837–839. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Finkel T, Deng CX and Mostoslavsky R:
Recent progress in the biology and physiology of sirtuins. Nature.
460:587–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kleszcz R, Paluszczak J and Baer-Dubowska
W: Targeting aberrant cancer metabolism-The role of sirtuins.
Pharmacol Rep. 67:1068–1080. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jeong SM, Hwang S and Seong RH: SIRT4
regulates cancer cell survival and growth after stress. Biochem
Biophys Res Commun. 470:251–256. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Feng J, Yan PF, Zhao HY, Zhang FC, Zhao WH
and Feng M: SIRT6 suppresses glioma cell growth via induction of
apoptosis, inhibition of oxidative stress and suppression of
JAK2/STAT3 signaling pathway activation. Oncol Rep. 35:1395–1402.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kiran S, Oddi V and Ramakrishna G: Sirtuin
7 promotes cellular survival following genomic stress by
attenuation of DNA damage, SAPK activation and p53 response. Exp
Cell Res. 331:123–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim HS, Vassilopoulos A, Wang RH, Lahusen
T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, et al: SIRT2
maintains genome integrity and suppresses tumorigenesis through
regulating APC/C activity. Cancer Cell. 20:487–499. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Benigni A, Perico L and Macconi D:
Mitochondrial dynamics is linked to longevity and protects from
End-organ injury: The emerging role of Sirtuin 3. Antioxid Redox
Signal. 25:185–199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh S, Kumar PU, Thakur S, Kiran S, Sen
B, Sharma S, Rao VV, Poongothai AR and Ramakrishna G:
Expression/localization patterns of sirtuins (SIRT1, SIRT2, and
SIRT7) during progression of cervical cancer and effects of sirtuin
inhibitors on growth of cervical cancer cells. Tumour Biol.
36:6159–6171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Azuma Y, Yokobori T, Mogi A, Altan B,
Yajima T, Kosaka T, Onozato R, Yamaki E, Asao T, Nishiyama M and
Kuwano H: SIRT6 expression is associated with poor prognosis and
chemosensitivity in patients with non-small cell lung cancer. J
Surg Oncol. 112:231–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang PY, Li G, Deng ZJ, Liu LY, Chen L,
Tang JZ, Wang YQ, Cao ST, Fang YX, Wen F, et al: Dicer interacts
with SIRT7 and regulates H3K18 deacetylation in response to DNA
damaging agents. Nucleic Acids Res. 44:3629–3642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Padmaja Divya S, Pratheeshkumar P, Son YO,
Vinod Roy R, Andrew Hitron J, Kim D, Dai J, Wang L, Asha P, Huang
B, et al: Arsenic induces insulin resistance in mouse adipocytes
and myotubes via oxidative stress-regulated mitochondrial
Sirt3-FOXO3a signaling pathway. Toxicol Sci. 146:290–300. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pacella-Ince L, Zander-Fox DL and Lane M:
Mitochondrial SIRT5 is present in follicular cells and is altered
by reduced ovarian reserve and advanced maternal age. Reprod Fertil
Dev. 26:1072–1083. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan H, Su L and Chen WY: The emerging and
diverse roles of sirtuins in cancer: A clinical perspective. Onco
Targets Ther. 6:1399–1416. 2013.PubMed/NCBI
|
|
17
|
Ahuja N, Schwer B, Carobbio S, Waltregny
D, North BJ, Castronovo V, Maechler P and Verdin E: Regulation of
insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase.
J Biol Chem. 282:33583–33592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ho L, Titus AS, Banerjee KK, George S, Lin
W, Deota S, Saha AK, Nakamura K, Gut P, Verdin E and
Kolthur-Seetharam U: SIRT4 regulates ATP homeostasis and mediates a
retrograde signaling via AMPK. Aging (Albany NY). 5:835–849. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Laurent G, German NJ, Saha AK, de Boer VC,
Davies M, Koves TR, Dephoure N, Fischer F, Boanca G, Vaitheesvaran
B, et al: SIRT4 coordinates the balance between lipid synthesis and
catabolism by repressing malonyl CoA decarboxylase. Mol Cell.
50:686–698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nasrin N, Wu X, Fortier E, Feng Y, Bare'
OC, Chen S, Ren X, Wu Z, Streeper RS and Bordone L: SIRT4 regulates
fatty acid oxidation and mitochondrial gene expression in liver and
muscle cells. J Biol Chem. 285:31995–32002. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haigis MC, Mostoslavsky R, Haigis KM,
Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos
GD, Karow M, Blander G, et al: SIRT4 inhibits glutamate
dehydrogenase and opposes the effects of calorie restriction in
pancreatic beta cells. Cell. 126:941–954. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Houtkooper RH, Pirinen E and Auwerx J:
Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol
Cell Biol. 13:225–238. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Csibi A, Fendt SM, Li C, Poulogiannis G,
Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T,
et al: The mTORC1 pathway stimulates glutamine metabolism and cell
proliferation by repressing SIRT4. Cell. 153:840–854. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jeong SM, Xiao C, Finley LW, Lahusen T,
Souza AL, Pierce K, Li YH, Wang X, Laurent G, German NJ, et al:
SIRT4 has tumor-suppressive activity and regulates the cellular
metabolic response to DNA damage by inhibiting mitochondrial
glutamine metabolism. Cancer Cell. 23:450–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen X, Lai X, Wu C, Tian Q, Lei T, Pan J
and Huang G: Decreased SIRT4 protein levels in endometrioid
adenocarcinoma tissues are associated with advanced AJCC stage.
Cancer Biomark. 19:419–424. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakahara Y, Yamasaki M, Sawada G, Miyazaki
Y, Makino T, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S,
Mimori K, et al: Downregulation of SIRT4 expression is associated
with poor prognosis in esophageal squamous cell carcinoma.
Oncology. 90:347–355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Igci M, Kalender ME, Borazan E, Bozgeyik
I, Bayraktar R, Bozgeyik E, Camci C and Arslan A: High-throughput
screening of Sirtuin family of genes in breast cancer. Gene.
586:123–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang G, Cui F, Yu F, Lu H, Zhang M, Tang
H and Peng Z: Sirtuin-4 (SIRT4) is downregulated and associated
with some clinicopathological features in gastric adenocarcinoma.
Biomed Pharmacother. 72:135–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang JX, Yi Y, Li YW, Cai XY, He HW, Ni
XC, Zhou J, Cheng YF, Jin JJ, Fan J and Qiu SJ: Down-regulation of
sirtuin 3 is associated with poor prognosis in hepatocellular
carcinoma after resection. BMC Cancer. 14:2972014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miyo M, Yamamoto H, Konno M, Colvin H,
Nishida N, Koseki J, Kawamoto K, Ogawa H, Hamabe A, Uemura M, et
al: Tumour-suppressive function of SIRT4 in human colorectal
cancer. Br J Cancer. 113:492–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blaveri E, Simko JP, Korkola JE, Brewer
JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P
and Waldman FM: Bladder cancer outcome and subtype classification
by gene expression. Clin Cancer Res. 11:4044–4055. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jeong SM, Lee A, Lee J and Haigis MC:
SIRT4 protein suppresses tumor formation in genetic models of
Myc-induced B cell lymphoma. J Biol Chem. 289:4135–4144. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fu L, Dong Q, He J, Wang X, Xing J, Wang
E, Qiu X and Li Q: SIRT4 inhibits malignancy progression of NSCLCs,
through mitochondrial dynamics mediated by the ERK-Drp1 pathway.
Oncogene. 36:2724–2736. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu Y, Yan Y, Principe DR, Zou X,
Vassilopoulos A and Gius D: SIRT3 and SIRT4 are mitochondrial tumor
suppressor proteins that connect mitochondrial metabolism and
carcinogenesis. Cancer Metab. 2:152014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lombardi L, Morelli F, Cinieri S, Santini
D, Silvestris N, Fazio N, Orlando L, Tonini G, Colucci G and
Maiello E: Adjuvant colon cancer chemotherapy: Where we are and
where we'll go. Cancer Treat Rev. 36(Suppl 3): S34–S41. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
AlShamaileh H, Wang T, Xiang D, Yin W,
Tran PH, Barrero RA, Zhang PZ, Li Y, Kong L, Liu K, et al:
Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate
colorectal cancer stem cells. Sci Rep. 7:58982017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Siesing C, Sorbye H, Dragomir A, Pfeiffer
P, Qvortrup C, Pontén F, Jirström K, Glimelius B and Eberhard J:
High RBM3 expression is associated with an improved survival and
oxaliplatin response in patients with metastatic colorectal cancer.
PLoS One. 12:e01825122017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Noordhuis P, Holwerda U, van Laar JA, van
der Wilt CL and Peters GJ: A non-radioactive sensitive assay to
measure 5-fluorouracil incorporation into DNA of solid tumors.
Nucleosides Nucleotides Nucleic Acids. 23:1481–1484. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Q, Meng F, Wang L, Mao Y, Zhou H, Hua
D, Zhang H and Wang W: A polymorphism in ABCC4 is related to
efficacy of 5-FU/capecitabine-based chemotherapy in colorectal
cancer patients. Sci Rep. 7:70592017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Raymond E, Faivre S, Woynarowski JM and
Chaney SG: Oxaliplatin: Mechanism of action and antineoplastic
activity. Semin Onco. 25(2 Suppl 5): S4–S12. 1998.
|
|
43
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: A multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Raymond E, Faivre S, Chaney S, Woynarowski
J and Cvitkovic E: Cellular and molecular pharmacology of
oxaliplatin. Mol Cancer Ther. 1:227–235. 2002.PubMed/NCBI
|
|
45
|
Wang L, Zhou H, Wang Y, Cui G and Di LJ:
CtBP maintains cancer cell growth and metabolic homeostasis via
regulating SIRT4. Cell Death Dis. 6:e16202015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Verdin E, Hirschey MD, Finley LW and
Haigis MC: Sirtuin regulation of mitochondria: Energy production,
apoptosis, and signaling. Trends Biochem Sci. 35:669–675. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu B, Che W, Xue J, Zheng C, Tang K,
Zhang J, Wen J and Xu Y: SIRT4 prevents hypoxia-induced apoptosis
in H9c2 cardiomyoblast cells. Cell Physiol Biochem. 32:655–662.
2013. View Article : Google Scholar : PubMed/NCBI
|
